Name: Jianjian Li
Position: Chair Professor
Email: jijli@ucdavis.edu
Address: Medical Building 401-1125, North District of Dushuhu Campus
Contact Phone: +86 512 65882451
I. Educational and Professional Experience
1990.08–1994.12 University of Iowa, Iowa City, IA, USA – Ph.D. in Tumor Biology
1985.01–1988.07 Fourth Military Medical University, Xi'an, China – M.D.
2. Professional Experience：
2026.05–present Soochow University, School of Radiation Medicine and Protection – Chair Professor
2024.08–present Xiangya Hospital, Central South University – Feifan Distinguished Professor
2024.07–present University of California, Davis, Department of Radiation Oncology – Professor (Retired)
2009.06–2024.06 University of California, Davis, Department of Radiation Oncology – Professor / Director
1999.01–2004.06 City of Hope National Medical Center, Division of Radiation Biology – Associate Professor / Group Leader
1995.01–1998.12 National Institutes of Health, Laboratory of Molecular Tumorigenesis – Postdoctoral Fellow
1988.08–1990.07 University of California, San Francisco, School of Radiation Oncology – Research Fellow
1985.01–1988.07 Fourth Military Medical University, School of Radiation Medicine – Lecturer
II. Research Focus
1. DNA damage and repair
2. Radiation sensitivity
3. Genomic instability
III. Project/Honor/Award
1. NIH/NCI, "A Decellularized Porcine Placenta Matrix Hydrogel for Management of Radiation-Induced Proctitis," 1 R41 CA272043-01A1, 06/2023–20xx, $400,000 – Principal Investigator
2. NIH/NCI, "Mitochondrial bioenergetics is associated with aggressive breast cancer growth," R01 CA213830-01, 01/2017–20xx, $1,962,500 – Principal Investigator
3. NIH/NCI, "Target MKP-1 for Therapy-resistant Breast Cancer Stem Cells," 1R01CA152313-01A1, 04/2011–20xx, $2,438,000 – Principal Investigator
4. 2004 – Purdue University, Provost's Seed for Success Award
5. 1989 – Radiation Research Society, Annual Meeting Young Investigator Award
6. 1988 – International Union Against Cancer (UICC), E. Roosevelt International Cancer Research Award
IV. Recent Five-Year Representative Research Outcomes
1. Huang J, Luo S, Shen J, Lee M, Chen R, Ma S, Sun LQ, Li JJ*. Cellular polarity pilots breast cancer progression and immunosuppression. Oncogene. 2025 Apr;44(12):783-793.
2. Zhang Y, Wang C, Li JJ*. Revisiting the role of mesenchymal stromal cells in cancer initiation, metastasis and immunosuppression. Exp. Hematol. Oncol. 2024 Jul 1;13(1):64.
3. Jiang N, Xie B, Xiao W, Fan M, Xu S, Duan Y, Hamsafar Y, Evans AC, Huang J, Zhou W, Lin X, Ye N, Wanggou S, Chen W, Jing D, Fragoso RC, Dugger BN, Wilson PF, Coleman MA, Xia S, Li X, Sun LQ, Monjazeb AM, Wang A, Murphy WJ, Kung HJ, Lam KS, Chen HW, Li JJ*. Fatty acid oxidation fuels glioblastoma radioresistance with CD47-mediated immune evasion. Nat. Commun. 2022;13(1):1511.
4. Candas-Green D, Xie B, Huang J, Fan M, Wang A, Menaa C, Zhang Y, Zhang L, Jing D, Azghadi S, Zhou W, Liu L, Jiang N, Li T, Gao T, Sweeney C, Shen R, Lin T-Y, Pan P-X, Ozpiskin OM, Woloschak G, Grdina DJ, Vaughan AT, Wang JM, Xia S, Monjazeb AM, Murphy WJ, Sun LQ, Chen HW, Lam KS, Weichselbaum RR, Li JJ*. Dual blockade of CD47 and HER2 eliminates radioresistant breast cancer cells. Nat. Commun. 2020;11(1):4591.
5. Li JJ*. Mitigating Coronavirus-Induced Acute Respiratory Distress Syndrome by Radiotherapy. iScience. 2020 Jun 26;23(6):101215.